Haleon plc - ADR

Organic Sales Growth Guidance: Haleon provided a guidance of 3% to 5% organic sales growth for 2026, indicating a sequential acceleration from the 3% growth achieved in 2025. This outlook is based on expected improvements in the U.S. market and strengthened competitiveness through strategic marketing investments and innovation.

Medium-Term Ambition: The company reiterated its medium-term growth ambition of 4% to 6%, despite experiencing organic sales growth below this range for the past two consecutive years. Confidence in returning to this range stems from expectations of stronger performance in emerging markets, particularly in India and China.

Category Performance: The cold and flu segment is underperforming due to a softer market; however, Haleon is executing plans to improve its Oral Health and Pain Relief categories. Oral Health, bolstered by successful products like Sensodyne and Parodontax, continues to see robust growth while Digestive Health faces challenges, particularly from private label competition.